These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8890711)

  • 1. Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone.
    Braess J; Kern W; Unterhalt M; Kaufmann CC; Ramsauer B; Schüssler M; Kaeser-Fröhlich A; Hiddemann W; Schleyer E
    Ann Hematol; 1996 Oct; 73(4):201-4. PubMed ID: 8890711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
    Braess J; Freund M; Hanauske A; Heil G; Kaufmann C; Kern W; Schüssler M; Hiddemann W; Schleyer E
    Leukemia; 1998 Oct; 12(10):1618-26. PubMed ID: 9766508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study.
    Kühr T; Eisterer W; Apfelbeck U; Linkesch W; Bechter O; Zabernigg A; Geissler K; Barbieri G; Duba C; Gastl G; Thaler J
    Leuk Res; 2000 Jul; 24(7):583-7. PubMed ID: 10867132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of complete remission from acute unclassified leukemia achieved by using a prodrug of ara C, stearyl-ara-CMP (YNK01)].
    Nishikawa M; Morita K; Komada F; Uemura Y; Kageyama S; Minami N; Deguchi K; Shirakawa S
    Gan No Rinsho; 1990 Oct; 36(12):2204-9. PubMed ID: 2232191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
    Maloisel F; Guerci A; Guyotat D; Ifrah N; Michallet M; Reiffers J; Tertain G; Blanc M; Bauduer F; Brière J; Abgrall JF; Pegourie-Bandelier B; Solary E; Cambier N; Coso D; Vilque JP; Delain M; Harousseau JL; Rousselot P; Belhadj K; Morice P; Attal J; Chabin M; Chastang C; Guilhot J; Guilhot F;
    Leukemia; 2002 Apr; 16(4):573-80. PubMed ID: 11960335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A new antileukemic drug, cytarabine ocfosfate].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1877-83. PubMed ID: 8379682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies].
    Ueda Y; Mori S; Ito T; Maesako Y; Konishi H; Yagiri Y
    Rinsho Ketsueki; 1998 May; 39(5):348-54. PubMed ID: 9637884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate.
    Arahata M; Shimizu Y; Asakura H; Nakao S
    J Hematol Oncol; 2015 Feb; 8():5. PubMed ID: 25652695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.
    Mollee P; Arthur C; Hughes T; Januszewicz H; Grigg A; Bradstock K; Wolf M; Gibson J; Schwarer AP; Spencer A; Browett P; Hawkins T; Seldon M; Herrmann R; Watson A; Seymour JF; Martin N; Shina S; Low C; Wright S; Rodwell R; Coulston J; Morton J; Blacklock H; Taylor D; Taylor KM
    Ann Oncol; 2004 Dec; 15(12):1810-5. PubMed ID: 15550587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous oral cytarabine ocfosfate with interferon-alpha-2b for patients with newly diagnosed chronic myeloid leukaemia: a pilot study.
    del Cañizo MC; Fisac MP; Galende J; Hurtado JA; Moro MJ; Rodriguez JA; Rivas JM; Tabernero MD;
    Br J Haematol; 2001 Dec; 115(3):541-4. PubMed ID: 11736933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful treatment of acute myelomonocytic leukemia developed from MDS with cytarabine ocfosfate (SPAC)].
    Wake A; Takazawa A; Serino Y; Tonai S; Nakanishi M; Murakami S; Ogawa R; Nagata K; Mori N; Nakata K
    Gan To Kagaku Ryoho; 1995 Feb; 22(3):395-8. PubMed ID: 7880111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)].
    Tsutsumi H; Kumakawa T; Hirai M; Kikukawa M; Arie Y; Mori M; Kodo H; Nakamura N; Murai Y; Mizutani R
    Nihon Ronen Igakkai Zasshi; 1995 Mar; 32(3):190-4. PubMed ID: 7596061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate].
    Takeuchi M; Kojima K; Takaba S; Isokawa M; Tanimizu M; Kimura F; Ohmoto E; Harada M
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):141-4. PubMed ID: 7826071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Successful treatment of acute myelogenous leukemia in an elderly patient with cytarabine ocfosfate].
    Inaba T; Shimazaki C; Tatsumi T; Yamagata N; Hirata T; Goto H; Fujita N; Nakagawa M; Fujita N; Miyazaki S
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):535-8. PubMed ID: 8129396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful treatment of myelodysplastic syndrome with cytarabine ocfosfate].
    Arai T; Narimiya S; Hayakawa K; Takaya T; Toshima S; Araki M; Uchida A; Yoshimi N; Shibuya C; Yasuda Y
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1085-8. PubMed ID: 8002627
    [No Abstract]   [Full Text] [Related]  

  • 16. A severe hepatic disorder with myelodysplastic syndrome, treated with cytarabine ocfosfate, in a dog.
    Ide K; Momoi Y; Minegishi M; Sekiguchi M; Konno K; Iwasaki T
    Aust Vet J; 2003; 81(1-2):47-9. PubMed ID: 15084010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Low-dose cytarabine ocfosfate therapy in an elderly acute myelogenous leukemia].
    Hamaoka R; Jozaki K; Amano T; Itoh H; Imai Y; Nishikawa M; Kurokawa M; Yonezawa T; Chinen Y
    Gan To Kagaku Ryoho; 1995 May; 22(6):819-22. PubMed ID: 7755392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
    Schleyer E; Braess J; Ramsauer B; Unterhalt M; Kaufmann C; Wilde S; Schüssler M; Hiddemann W
    Leukemia; 1995 Jun; 9(6):1085-90. PubMed ID: 7596174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent development of antitumor antimetabolites in Japan--cytosine arabinoside analogues].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1997 May; 24(7):761-70. PubMed ID: 9170512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hypoplastic leukemia successfully treated by oral administration with cytarabine ocfosfate].
    Okuyama Y; Kitazume K; Iwabe K; Usuki K; Urabe A
    Rinsho Ketsueki; 1994 Jun; 35(6):593-7. PubMed ID: 8078195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.